{
    "clinical_study": {
        "@rank": "109127", 
        "arm_group": {
            "arm_group_label": "Sitagliptin", 
            "arm_group_type": "Experimental", 
            "description": "Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3."
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this trial is to assess the efficacy and safety of sitagliptin in\n      enhancing engraftment following umbilical cord blood transplantation (recovery of blood\n      counts after transplant)."
        }, 
        "brief_title": "Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant", 
        "condition": [
            "Acute Myeloid Leukemia", 
            "Acute Lymphoid Leukemia", 
            "Hematopoetic Myelodysplasia", 
            "Leukemia, Myelogenous, Chronic", 
            "Lymphoma, Non-Hodgkin"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Umbilical cord blood (UCB) is more commonly used for transplantation in children but is\n      being used in adults more often. However, because adults are larger than children, the\n      relatively smaller stem cell dose in UCB is major limitation for transplantation in adults\n      and engraftment can be delayed. This study is trying to find out if the drug sitagliptin can\n      be used to increase and speed up engraftment in adults receiving UCB transplantation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have one of the following disease types:\n\n               -  Acute myeloid leukemia (AML) with disease features as described in the protocol.\n\n               -  Acute lymphoblastic leukemia (ALL) with disease features as described in the\n                  protocol.\n\n               -  Myelodysplasia with disease features as described in the protocol.\n\n               -  Chronic myelogenous leukemia (CML) with disease features as described in the\n                  protocol.\n\n               -  Patients with aggressive non-Hodgkin's lymphoma (NHL), including diffuse large\n                  cell lymphoma, mediastinal B-cell lymphoma, transformed lymphoma, mantle cell\n                  lymphoma, and peripheral T cell lymphoma, who also have one of the disease\n                  features as described in the protocol.\n\n          -  At least 35 days following start of preceding leukemia induction cytotoxic\n             chemotherapy.\n\n          -  For patients in remission, there should be no readily available consenting\n             HLA-matched related donor who is either matched fully matched or mismatched at only\n             one locus of HLA-A, -B, and DRB1.\n\n          -  No availability of a readily available HLA-matched volunteer unrelated donor (8 of 8\n             allele match at HLA-A, -B, -C and -DRB1).\n\n          -  Patients must have a matched or partially matched UCB unit with >/= 2.5 x10^7\n             nucleated cells/kg of recipient weight at the time of cryopreservation.\n\n          -  No current uncontrolled bacterial, viral or fungal infection (defined as currently\n             taking medication and progression of clinical symptoms).\n\n          -  No HIV disease.\n\n          -  Non pregnant and non-nursing.\n\n          -  Required baseline laboratory values as described in the protocol.\n\n          -  Signed written informed consent.\n\n        Exclusion Criteria:\n\n          -  Symptomatic uncontrolled coronary artery disease or congestive heart failure.\n\n          -  Severe hypoxemia with room air PaO2<70, supplemental oxygen dependence, or DLCO<50%\n             predicted.\n\n          -  Patients with central nervous system (CNS) involvement refractory to intrathecal\n             chemotherapy.\n\n          -  Prior allogeneic or autologous hematopoietic stem cell transplant in the last 6\n             months.\n\n          -  Patients who are taking other insulin secretagogues and/or insulin.\n\n          -  Patients who have hypersensitivity to sitagliptin.\n\n          -  Patients with a history of pancreatitis, cholelithiasis, alcoholism, or fasting\n             hypertriglyceridemia (> 2 x ULN)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720264", 
            "org_study_id": "1208009261; HL112669", 
            "secondary_id": "1R01HL112669-01"
        }, 
        "intervention": {
            "arm_group_label": "Sitagliptin", 
            "description": "Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.", 
            "intervention_name": "Sitagliptin", 
            "intervention_type": "Drug", 
            "other_name": "Januvia"
        }, 
        "intervention_browse": {
            "mesh_term": "Sitagliptin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "email": "llwood@iupui.edu", 
                "last_name": "Lisa Wood, RN", 
                "phone": "317-944-1781"
            }, 
            "contact_backup": {
                "email": "ssfarag@iupui.edu", 
                "last_name": "Sherif Farag, MBBS, PhD", 
                "phone": "317-274-0843"
            }, 
            "facility": {
                "address": {
                    "city": "Indianapolis", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "46202"
                }, 
                "name": "Indiana University Melvin and Bren Simon Cancer Center"
            }, 
            "investigator": {
                "last_name": "Sherif Farag, MBBS, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies", 
        "overall_contact": {
            "email": "llwood@iupui.edu", 
            "last_name": "Lisa L Wood, RN", 
            "phone": "317-944-1781"
        }, 
        "overall_contact_backup": {
            "email": "ssfarag@iupui.edu", 
            "last_name": "Sherif Farag, MBBS, PhD", 
            "phone": "317-278-0843"
        }, 
        "overall_official": {
            "affiliation": "Indiana University", 
            "last_name": "Sherif S Farag, M.B.B.S., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this phase II study is to determine if systemic inhibition of CD26 can result in neutrophil engraftment in 70% or more of patients by day +30 after transplantation, with a rate of <50% considered unacceptable.", 
            "measure": "The percent of subjects engrafting by day +30 after transplantation", 
            "safety_issue": "No", 
            "time_frame": "Day 0 to Day +30 post transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720264"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to neutrophil engraftment", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 until first consecutive 3 days with ANC >/= 0.5 x 10^9/L"
            }, 
            {
                "measure": "Time to platelet engraftment", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 until first consecutive 7 days where platelet count is >/= 20 x 10^9/L"
            }, 
            {
                "description": "Graft failure is defined as lack of neutrophil engraftment by Day +100 after transplantation in patients surviving a minimum of 14 days.", 
                "measure": "Number of subjects with primary graft failure", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 to Day +100"
            }, 
            {
                "description": "Non-hematological toxicity will be graded and described according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.", 
                "measure": "Number of subjects with Grade 3 and 4 non-hematological toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 to end of study"
            }, 
            {
                "description": "Acute Graft versus Host Disease will be based on the modified Keystone Grading Scale for skin, liver and gastrointestinal symptome (Stage 0-4 for each organ).", 
                "measure": "Number of subjects with acute GvHD at Day +100", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to Day +100"
            }, 
            {
                "description": "Chronic Graft versus Host Disease will be based on Filipovich et al. consensus document (BB&MT 2005) and Akpek et al. chronic GvHD grading system article (Blood 2003).", 
                "measure": "Number of subjects with chronic GvHD at 1 year post transplant", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to 1 year post transplant"
            }, 
            {
                "description": "Acute Graft versus Host Disease will be based on the modified Keystone Grading Scale for skin, liver and gastrointestinal symptoms (Stage 0-4 for each organ).", 
                "measure": "Grade of acute GvHD at 1 year post transplantation.", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to 1 year post transplantation"
            }, 
            {
                "description": "Chronic Graft versus Host Disease will be based on Filipovich et al. consensus document (BB&MT 2005) and Akpek et al. chronic GVHD grading system (Blood 2003).", 
                "measure": "Grade of chronic GvHD at Day +100", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to Day +100"
            }, 
            {
                "description": "Chronic Graft versus Host Disease will be based on Filipovich et al. consensus article (BB&MT 2005) and Akpek et al. chronic GVHD grading system article (Blood 2003).", 
                "measure": "Grade of chronic GvHD at 1 year post transplantation", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to 1 year post transplantation"
            }, 
            {
                "description": "Acute Graft versus Host Disease will be based on the modified Keystone Grading Scale for skin, liver and gastrointestinal symptome (Stage 0-4 for each organ).", 
                "measure": "Number of subjects with acute GvHD at 1 year post transplantation", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to 1 year post transplantation"
            }, 
            {
                "description": "Chronic Graft versus Host Disease will be based on Filipovich et al. consensus article (BB&MT 2005) and Akpek et al. chronic GVHD grading system (Blood 2003).", 
                "measure": "Number of subjects with chronic GVHD at Day 100.", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to Day +100"
            }, 
            {
                "description": "Acute Graft versus Host Disease will be based on the modified Keystone Grading Scale for skin, liver and gastrointestinal symptoms (stage 0-4 for each organ).", 
                "measure": "Grade of acute GvHD at Day +100", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to +100"
            }, 
            {
                "measure": "Number of subjects with transplant-related mortality at 6 months post transplant", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 to 6 months post transplant"
            }, 
            {
                "measure": "Time to disease relapse", 
                "safety_issue": "No", 
                "time_frame": "Day 0 until disease relapse"
            }, 
            {
                "measure": "Time until death", 
                "safety_issue": "No", 
                "time_frame": "Day 0 until death"
            }, 
            {
                "measure": "plasma levels of sitagliptin", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 2, 4, 6 hrs after first dose; before 2nd dose on Day -1; before first daily dose on Day 0, +1, +2, +3; before last dose and 2, 4, 6, 12, 24 after last dose."
            }, 
            {
                "measure": "Percent inhibition of DPP-IV relative to baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 2, 4, 6 hrs after first dose; before 2nd dose on Day -1; before first daily dose on Day 0, +1, +2, +3; 24 hours after last dose."
            }
        ], 
        "source": "Indiana University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Indiana University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}